125 related articles for article (PubMed ID: 11422606)
41. Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.
Brodie MJ; Forrest G; Rapeport WG
Br J Clin Pharmacol; 1983 Dec; 16(6):747-9. PubMed ID: 6661364
[TBL] [Abstract][Full Text] [Related]
42. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.
Hung CC; Chang WL; Ho JL; Tai JJ; Hsieh TJ; Huang HC; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Jan; 13(2):159-69. PubMed ID: 22188362
[TBL] [Abstract][Full Text] [Related]
43. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy.
Sennoune S; Iliadis A; Bonneton J; Barra Y; Genton P; Mesdjian E
Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722
[TBL] [Abstract][Full Text] [Related]
44. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
Patsalos PN
Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
[TBL] [Abstract][Full Text] [Related]
45. Valproate population pharmacokinetics in children.
Serrano BB; García Sánchez MJ; Otero MJ; Buelga DS; Serrano J; Domínguez-Gil A
J Clin Pharm Ther; 1999 Feb; 24(1):73-80. PubMed ID: 10319910
[TBL] [Abstract][Full Text] [Related]
46. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
Mahmood I; Chamberlin N
Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
[TBL] [Abstract][Full Text] [Related]
47. [Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome].
Kholodov LE; Prityko AG; Ivanova ES; Sokolov AV; Tishchenkova IF; Dubrovina LIu; Postnikov SS; Tatarinov PA; Kopanev IuA; Veselov NK
Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(3):35-40. PubMed ID: 7571921
[TBL] [Abstract][Full Text] [Related]
48. Determination of serum carbamazepine concentration using dried blood spot specimens for resource-limited settings.
Das S; Fleming DH; Mathew BS; Winston A B; Prabhakar AT; Alexander M
Hosp Pract (1995); 2017 Apr; 45(2):46-50. PubMed ID: 28353375
[TBL] [Abstract][Full Text] [Related]
49. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
50. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.
Sachdeo RC; Sachdeo SK; Walker SA; Kramer LD; Nayak RK; Doose DR
Epilepsia; 1996 Aug; 37(8):774-80. PubMed ID: 8764818
[TBL] [Abstract][Full Text] [Related]
51. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication.
Svinarov DA; Pippenger CE
Ther Drug Monit; 1996 Dec; 18(6):660-5. PubMed ID: 8946662
[TBL] [Abstract][Full Text] [Related]
52. Carbamazepine adverse drug reactions.
Fricke-Galindo I; LLerena A; Jung-Cook H; López-López M
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):705-718. PubMed ID: 29898616
[TBL] [Abstract][Full Text] [Related]
53. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation.
Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E
Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286
[TBL] [Abstract][Full Text] [Related]
54. Developmental and therapeutic pharmacology of antiepileptic drugs.
Miura H
Epilepsia; 2000; 41 Suppl 9():2-6. PubMed ID: 11156504
[TBL] [Abstract][Full Text] [Related]
55. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
[TBL] [Abstract][Full Text] [Related]
56. Correlation of serum and salivary carbamazepine concentration in epileptic patients: implications for therapeutic drug monitoring.
Vasudev A; Tripathi KD; Puri V
Neurol India; 2002 Mar; 50(1):60-2. PubMed ID: 11960153
[TBL] [Abstract][Full Text] [Related]
57. Carbamazepine-risperidone interactions in patients with epilepsy.
Mula M; Monaco F
Clin Neuropharmacol; 2002; 25(2):97-100. PubMed ID: 11981236
[TBL] [Abstract][Full Text] [Related]
58. [Influence of coadministered antiepileptic drugs on serum antiepileptic drug concentrations in epileptic patients -quantitative analysis based on suitable transforming factor].
Fukuoka N
Yakugaku Zasshi; 2004 Jul; 124(7):443-50. PubMed ID: 15235228
[TBL] [Abstract][Full Text] [Related]
59. An experimental design for finding of minimum dosage of carbamazepine and valproate in preventing of seizure attacks.
Samaei A; Nobahar M; Vafaei AA
Pak J Pharm Sci; 2009 Apr; 22(2):180-3. PubMed ID: 19339229
[TBL] [Abstract][Full Text] [Related]
60. Rapid switchover to carbamazepine using pharmacokinetic parameters.
Kanner AM; Bourgeois BF; Hasegawa H; Hutson P
Epilepsia; 1998 Feb; 39(2):194-200. PubMed ID: 9578000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
